Literature DB >> 24259437

Performance of gadoxetic acid-enhanced MRI for detecting hepatocellular carcinoma in recipients of living-related-liver-transplantation: comparison with dynamic multidetector row computed tomography and angiography-assisted computed tomography.

Daisuke Kakihara1, Akihiro Nishie, Noboru Harada, Ken Shirabe, Tsuyoshi Tajima, Yoshiki Asayama, Kousei Ishigami, Tomohiro Nakayama, Yukihisa Takayama, Daisuke Okamoto, Nobuhiro Fujita, Junji Kishimoto, Hiroshi Honda.   

Abstract

PURPOSE: To clarify the diagnostic performance of gadoxetic acid-enhanced MRI for the detection of hepatocellular carcinoma (HCC) in recipients of living related-liver transplantation (LRLT).
MATERIALS AND METHODS: This retrospective study group consisted of 15 patients with 61 HCCs who each underwent multidetector row computed tomography (MDCT), gadoxetic acid-enhanced MRI, and angiography-assisted computed tomography (CT) before LRLT. The three modalities were compared for their ability to detect HCC. Two blinded readers independently reviewed the images obtained by each modality for the presence of HCC on a segment-by-segment basis using a 5-point confidence scale. The diagnostic performance of the modalities was evaluated in a receiver operating characteristic (ROC) analysis. The area under the ROC curve (Az), sensitivity, specificity, and accuracy were compared for the three modalities.
RESULTS: No significant difference in Az, sensitivity, specificity, or accuracy was obtained among gadoxetic acid-enhanced MRI, MDCT, and angiography-assisted CT for both readers. For reader 1, the sensitivity (55.6%) and the accuracy (84.7%) of angiography-assisted CT were significantly higher than those of MDCT (33.3% and 78.0%) (P < 0.05).
CONCLUSION: Gadoxetic acid-enhanced MRI has a relatively high diagnostic ability to detect HCC even in recipients of LRLT, equivalent to the abilities of MDCT and angiography-assisted CT.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  MDCT; MRI; angiography-assisted CT; gadoxetic acid; hepatocellular carcinoma; living-related-liver-transplantation

Mesh:

Substances:

Year:  2013        PMID: 24259437     DOI: 10.1002/jmri.24454

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  7 in total

1.  Perfusion computed tomography for detection of hepatocellular carcinoma in patients with liver cirrhosis.

Authors:  Michael A Fischer; Nikolaos Kartalis; Aristeidis Grigoriadis; Louiza Loizou; Per Stål; Bertil Leidner; Peter Aspelin; Torkel B Brismar
Journal:  Eur Radiol       Date:  2015-04-23       Impact factor: 5.315

Review 2.  Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Tin Nadarevic; Vanja Giljaca; Agostino Colli; Mirella Fraquelli; Giovanni Casazza; Damir Miletic; Davor Štimac
Journal:  Cochrane Database Syst Rev       Date:  2021-10-06

Review 3.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

4.  Hyperintensity at fat spared area in steatotic liver on the hepatobiliary phase MRI.

Authors:  Emre Ünal; İlkay Sedakat İdilman; Ali Devrim Karaosmanoğlu; Mustafa Nasuh Özmen; Deniz Akata; Muşturay Karcaaltıncaba
Journal:  Diagn Interv Radiol       Date:  2019-11       Impact factor: 2.630

Review 5.  Gadoxetate-Enhanced MRI as a Diagnostic Tool in the Management of Hepatocellular Carcinoma: Report from a 2020 Asia-Pacific Multidisciplinary Expert Meeting.

Authors:  Cher Heng Tan; Shu-Cheng Chou; Nakarin Inmutto; Ke Ma; RuoFan Sheng; YingHong Shi; Zhongguo Zhou; Akira Yamada; Ryosuke Tateishi
Journal:  Korean J Radiol       Date:  2022-05-09       Impact factor: 7.109

6.  Diagnostic performance of contrast-enhanced multidetector computed tomography and gadoxetic acid disodium-enhanced magnetic resonance imaging in detecting hepatocellular carcinoma: direct comparison and a meta-analysis.

Authors:  Jin Guo; Youngkwon Seo; Shuo Ren; Sunwoo Hong; Dongki Lee; Soyoun Kim; Yuanyuan Jiang
Journal:  Abdom Radiol (NY)       Date:  2016-10

7.  Optimal Combination of Features on Gadoxetate Disodium-enhanced MR Imaging for Non-invasive Differential Diagnosis of Hepatocellular Carcinoma: The JAMP-HCC Study.

Authors:  Shintaro Ichikawa; Utaroh Motosugi; Hiroyuki Morisaka; Kazuto Kozaka; Satoshi Goshima; Tomoaki Ichikawa
Journal:  Magn Reson Med Sci       Date:  2020-02-27       Impact factor: 2.471

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.